Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$20.57 -0.5%	$20.50	$13.30 ▼ $30.03	$1.23B	0.93	373,029 shs	339,937 shs
GPCR Structure Therapeutics	$19.34 +1.8%	$19.11	$13.22 ▼ $45.37	$1.12B	-1.89	860,416 shs	255,237 shs
LCTX Lineage Cell Therapeutics	$1.22 -0.4%	$1.04	$0.37 ▼ $1.31	$277.46M	1.66	1.90 million shs	568,651 shs
TLRY Tilray Brands	$1.47 +6.9%	$0.72	$0.35 ▼ $1.88	$1.62B	1.85	42.55 million shs	72.22 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	+1.77%	+5.19%	+0.05%	+16.57%	-8.33%
GPCR Structure Therapeutics	+0.96%	+2.32%	+4.00%	-15.25%	-53.74%
LCTX Lineage Cell Therapeutics	-2.40%	+2.52%	+4.27%	+77.84%	+28.68%
TLRY Tilray Brands	-5.52%	+29.25%	+95.80%	+194.88%	-21.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELVN Enliven Therapeutics	2.768 of 5 stars	3.5	2.0	2.3	4.2	0.0
GPCR Structure Therapeutics	2.8687 of 5 stars	3.5	3.0	2.9	1.7	0.6
LCTX Lineage Cell Therapeutics	2.4135 of 5 stars	3.5	1.0	1.8	3.3	0.6
TLRY Tilray Brands	1.8647 of 5 stars	3.2	1.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	3.00	Buy	$41.20	100.29% Upside
GPCR Structure Therapeutics	3.00	Buy	$75.71	291.53% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.25	249.79% Upside
TLRY Tilray Brands	2.33	Hold	$1.94	32.25% Upside

Current Analyst Ratings Breakdown

Latest LCTX, TLRY, ELVN, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
8/25/2025	TLRY Tilray Brands	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $2.00
8/14/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
8/7/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
8/7/2025	GPCR Structure Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$92.00 ➝ $90.00
8/7/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$89.00 ➝ $87.00
8/5/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$8.25 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$13.40 per share	N/A
LCTX Lineage Cell Therapeutics	$9.50M	29.21	N/A	N/A	$0.21 per share	5.79
TLRY Tilray Brands	$210.48M	7.66	$0.15 per share	10.03	$1.40 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$89.02M	-$2.00	N/A	N/A	N/A	N/A	-29.15%	-27.88%	11/12/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$1.05	N/A	N/A	N/A	N/A	-21.31%	-20.34%	11/12/2025 (Estimated)
LCTX Lineage Cell Therapeutics	-$18.61M	-$0.12	N/A	N/A	N/A	-374.84%	-20.00%	-12.93%	11/13/2025 (Estimated)
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest LCTX, TLRY, ELVN, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
8/6/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	-$0.36	-$0.08	-$0.36	N/A	N/A
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	32.58	32.58
GPCR Structure Therapeutics	N/A	20.48	20.48
LCTX Lineage Cell Therapeutics	N/A	4.08	4.08
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
GPCR Structure Therapeutics	91.78%
LCTX Lineage Cell Therapeutics	62.47%
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	25.90%
GPCR Structure Therapeutics	5.60%
LCTX Lineage Cell Therapeutics	26.80%
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	59.24 million	43.89 million	Optionable
GPCR Structure Therapeutics	136	57.60 million	54.37 million	Optionable
LCTX Lineage Cell Therapeutics	60	228.36 million	167.16 million	Not Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

LCTX, TLRY, ELVN, and GPCR Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Shares Down 5.9% - Should You Sell?

3 hours ago | marketbeat.com

Jefferies Raises Tilray (TLRY) Price Target on Potential Cannabis Rescheduling

August 28 at 8:10 AM | insidermonkey.com

Tilray Medical Expands Presence in Germany with Introduction of New Good Supply Medical Cannabis Strains

August 28 at 7:00 AM | globenewswire.com

Tilray Brands, Inc.: Tilray Brands Successfully Regains Compliance with Nasdaq's Minimum Bid Price Requirement

August 28 at 5:33 AM | finanznachrichten.de

Why Tilray (TLRY) Shares Are Plunging Today

August 28 at 5:33 AM | msn.com

Tilray Brands (NASDAQ:TLRY) Sees Unusually-High Trading Volume Following Analyst Upgrade

August 28 at 2:58 AM | americanbankingnews.com

Tilray Brands, Inc. (TLRY) Stock Falls Amid Market Uptick: What Investors Need to Know

August 27 at 7:00 PM | zacks.com

Tilray Brands Successfully Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

August 27 at 5:11 PM | financialpost.comF

Tilray Brands, Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement

August 27 at 5:11 PM | quiverquant.comQ

Tilray Brands Successfully Regains Compliance with Nasdaq's Minimum Bid Price Requirement

August 27 at 5:02 PM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Shares Up 3.2% on Analyst Upgrade

August 27 at 11:18 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Sees Strong Trading Volume After Analyst Upgrade

August 27 at 10:15 AM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Trading 3.2% Higher After Analyst Upgrade

August 27 at 2:29 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up on Analyst Upgrade

August 27 at 2:50 AM | americanbankingnews.com

Tilray: Sell The U.S. Rescheduling Rally

August 26 at 5:14 PM | seekingalpha.com

Why Tilray (TLRY) Stock Is Up Today

August 26 at 5:05 PM | msn.com

US cannabis stocks rally as Trump backs rescheduling

August 26 at 4:04 PM | proactiveinvestors.com

Tilray Brands (TLRY) Jumps 23% as Analyst Goes Bullish on Cannabis Prospects

August 26 at 1:32 PM | insidermonkey.com

Here's why Tilray stock price is soaring and why it may crash soon

August 26 at 1:05 PM | invezz.comI

Tilray Brands (NASDAQ:TLRY) Trading Up 18.7% on Analyst Upgrade

August 26 at 11:13 AM | marketbeat.com

Tilray Brands shares gain as analysts boost price target on cannabis rescheduling optimism

August 26 at 11:13 AM | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LCTX, TLRY, ELVN, and GPCR Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$20.57 -0.11 (-0.53%)

As of 03:30 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics NASDAQ:GPCR

$19.34 +0.34 (+1.78%)

As of 03:30 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.22 -0.01 (-0.41%)

As of 03:29 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Tilray Brands NASDAQ:TLRY

$1.46 +0.10 (+6.93%)

As of 03:30 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time